Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future...
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this monththat allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.showed that Wegovy cut the risk of heart attack, stroke and other problems by 20% versus a placebo, or dummy drug, in such patients.
Private insurers are evaluating the guidance — and the new indication for Wegovy — before making coverage decisions, said a spokesperson for AHIP, America’s Health Insurance Plans, an industry trade group.At issue has been whether the cost of the expensive medications will be offset by the savings of reduced spending on medical care related to obesity — and, now, heart disease.for more than a year, according to the FDA.
“These plant fibers, which are cheap and available over-the-counter, could benefit a wide group of people in these cash-strapped times."The Princess of Wales underwent abdominal surgery at the private London Clinic in January - where an investigation has been launched around a major security breach involving Kate's medical records.Richard Simmons says a 'strange looking bump' under his eye was skin cancer.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wegovy to be covered by US Medicare for heart disease patientsExplore stories from Atlantic Canada.
Read more »
Eli Lilly and Novo Nordisk's Diabetes Drugs Being Studied for Other Health BenefitsEli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are being investigated for potential health benefits beyond diabetes treatment. A study is examining whether Novo's Wegovy can reduce alcohol intake in patients with early Alzheimer's disease. Another study is testing Novo's semaglutide in combination with clot removal therapy for stroke patients. Lilly is also conducting research on the effects of their drugs on Alzheimer's disease and obesity.
Read more »
Company at heart of ArriveCan scandal banned from bidding on federal contractsGC Strategies, the company at the heart of the scandal surrounding the ArriveCan app, has been banned from participating in federal procurements with security requirements.
Read more »
Feds suspend security status of company at heart of ArriveCan controversyThe Hill Times
Read more »
Diet drinks may boost risk of dangerous heart condition by 20 per cent, study saysDrinking two litres or more per week of artificially sweetened beverages raised the risk of an irregular heartbeat called atrial fibrillation by 20 per cent when compared to people who drank none, a new study found.
Read more »
New clot-busting intervention provided by Prince George paramedics saving lives of heart attack patientsCollaborative Heart Attack Management Program (CHAMP) restoring heart function in the back of an ambulance, minimizing hospital stays and reducing heath care costs
Read more »